Why we are called Trojantec
Stem cells & cancer stem cells
Trojan peptide antennapedia
Notch signaling in human disease
Notch pathway in human breast cancer
Why we are called Trojantec?
Trojantec to present at the 2013 Asco Annual Meeting
AACR Annual Meeting, April 6-10, 2013, Walter E. Convention Center, Washington, DC, USA
RECOMBINANT PROTEIN THERAPEUTICS, CHI's 12th Annual PepTalk, January 21, 2013, Palm Springs Convention Center, Palm Springs, California, USA
ESMO 2012, Vienna, Austria: Friday 28 September - Tuesday 2 October
New treatments against cancer and cancer stem cells
ASCO ANNUAL MEETING June 1-5, 2012, CHICAGO, IL.
AACR ANNUAL MEETING, March 31- April 4, 2012, CHICAGO, IL.
Trojantec raises funds for research and drug development in cancer and cancer stem cell therapeutics
AACR ANNUAL MEETING 2011, ORLANDO, FLORIDA.
Trojantec raises funds for research and drug development in cancer stem cell therapeutics
Trojantec raises funds to advance novel therapeutics
CANCER STEM CELLS CONFERENCE, CAMBRIDGE, MA, USA
European Patent Granted
Presentation by the Company's Chairman
Winners announced in London Technology Fund Competition 2009
ECCO 15 and the 34th ESMO Multidisciplinary Congress, held from the 20th - 24th of September 2009 in Berlin, Germany
Annual Meeting of ASCO held at Orlando, Florida, May 29th - June 2nd, 2009
Annual Conference of AACR held at Denver, Colorado
The 20th International Congress on anti-cancer treatments
San Diego Convention Centre
MARIANNA LORDOS CANCER CONFERENCE, 29 FEBRUARY- 2 MARCH 2008
The Role of Cancer Stem Cells in the Initiation and Propagation of Tumorigenesis
The 2nd UK Cancer Stem Cell Meeting
Trojantec Ltd participated at the Antibodies-Europe Conference held in Vienna, Austria 7-8 November 2007
Trojantec Ltd participated at the "The Notch meeting" held in Athens, Greece 23-27 September 2007
Trojantec Announces Data On Notch/numb Signaling Therapeutics To Be Presented At Cancer Stem Cell Conference
Trojantec announces participation in Cancer Conference
Trojantec announces participation in Cancer Stem Cells Conference
Trojantec announces participation in Keynote Symposium
Trojantec is awarded a Research Grant by The Research Promotion Foundation
Trojantec Selects First Lead Candidate for Advanced Preclinical Development
Trojantec to Present at a Cancer Stem Cells Conference in Myconos, Greece
Trojantec along with six other European Groups and Companies is awarded a Research Grant by The European Union
Cancer Research Journal Publishes Data from studies in Notch signaling in human breast cancer
© 2007-2012 Trojantec ltd. All rights reserved.